Literature DB >> 20051374

Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.

David L McCormick1, Jonathan M Phillips, Thomas L Horn, William D Johnson, Vernon E Steele, Ronald A Lubet.   

Abstract

Oral squamous cell carcinomas induced in rats by 4-nitroquinoline-1-oxide (NQO) show substantial overexpression of cyclooxygenase-2 (COX-2) when compared with adjacent phenotypically normal oral tissues. By contrast, neither 5-lipoxygenase (LOX) nor 12-LOX is overexpressed in rat oral cancers. Two chemoprevention studies were done to test the resulting hypothesis that COX-2 is a useful target for oral cancer chemoprevention in the rat. In both studies, male F344 rats received drinking water exposure to NQO (20 ppm) for 10 weeks, followed by administration of chemopreventive agents from week 10 until study termination at week 26. In the first study, groups of rats were fed basal diet (control), or basal diet supplemented with the selective COX-2 inhibitor celecoxib (500 or 1,500 mg/kg diet), the nonselective COX inhibitor piroxicam (50 or 150 mg/kg diet), or the 5-LOX inhibitor zileuton (2,000 mg/kg diet). In the second study, rats were fed basal diet (control) or basal diet supplemented with nitric oxide-naproxen (180 or 90 mg/kg diet), a nonselective COX inhibitor that shows reduced gastrointestinal toxicity. When compared with dietary controls, celecoxib decreased oral cancer incidence, cancer invasion score, and cancer-related mortality. Piroxicam decreased cancer-related mortality and cancer invasion score, whereas nitric oxide-naproxen decreased oral cancer incidence and cancer invasion score. By contrast, zileuton showed no chemopreventive activity by any parameter assessed. These data show that both selective and nonselective inhibitors of COX-2 can prevent NQO-induced oral carcinogenesis in rats. The chemopreventive activity of COX inhibitors may be linked to overexpression of their enzymatic target in incipient oral neoplasms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20051374      PMCID: PMC2804934          DOI: 10.1158/1940-6207.CAPR-09-0151

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  33 in total

1.  Current problems with non-specific COX inhibitors.

Authors:  P McGettigan; D Henry
Journal:  Curr Pharm Des       Date:  2000-11       Impact factor: 3.116

2.  Nordihydroguaiaretic acid suppression of rat mammary carcinogenesis induced by N-methyl-N-nitrosourea.

Authors:  D L McCormick; A M Spicer
Journal:  Cancer Lett       Date:  1987-10-30       Impact factor: 8.679

3.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

Review 4.  Over-the-counter analgesics: a toxicology perspective.

Authors:  Alison Jones
Journal:  Am J Ther       Date:  2002 May-Jun       Impact factor: 2.688

5.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Authors:  Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Patrice Matchaba; Alberto Gimona; Christopher J Hawkey
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

Review 6.  The pathology of oral cancer.

Authors:  D Murray Walker; George Boey; Louise A McDonald
Journal:  Pathology       Date:  2003-10       Impact factor: 5.306

Review 7.  Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis.

Authors:  Douglas A Corley; Karla Kerlikowske; Rajiv Verma; Patricia Buffler
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

Review 8.  NSAIDs and chemoprevention.

Authors:  Chinthalapally V Rao; Bandaru S Reddy
Journal:  Curr Cancer Drug Targets       Date:  2004-02       Impact factor: 3.428

9.  Modulation of rat mammary carcinogenesis by indomethacin.

Authors:  D L McCormick; M J Madigan; R C Moon
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

10.  Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent.

Authors:  D L McCormick; R C Moon
Journal:  Br J Cancer       Date:  1983-12       Impact factor: 7.640

View more
  18 in total

1.  Proapoptotic, anti-cell proliferative, anti-inflammatory and anti-angiogenic potential of carnosic acid during 7,12 dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis.

Authors:  Duraisamy Rajasekaran; Shanmugam Manoharan; Simon Silvan; Krishnamoorthy Vasudevan; Nagarethinam Baskaran; Duraisamy Palanimuthu
Journal:  Afr J Tradit Complement Altern Med       Date:  2012-10-01

2.  Ethanol promotes chemically induced oral cancer in mice through activation of the 5-lipoxygenase pathway of arachidonic acid metabolism.

Authors:  Yizhu Guo; Xin Wang; Xinyan Zhang; Zheng Sun; Xiaoxin Chen
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-31

3.  Modulation by aspirin and naproxen of nucleotide alterations and tumors in the lung of mice exposed to environmental cigarette smoke since birth.

Authors:  Sebastiano La Maestra; Francesco D'Agostini; Alberto Izzotti; Rosanna T Micale; Luca Mastracci; Anna Camoirano; Roumen Balansky; James E Trosko; Vernon E Steele; Silvio De Flora
Journal:  Carcinogenesis       Date:  2015-10-13       Impact factor: 4.944

4.  The use of animal models for cancer chemoprevention drug development.

Authors:  Vernon E Steele; Ronald A Lubet
Journal:  Semin Oncol       Date:  2010-08       Impact factor: 4.929

5.  5MeCDDO Blocks Metabolic Activation but not Progression of Breast, Intestine, and Tongue Cancers. Is Antioxidant Response Element a Prevention Target?

Authors:  Ronald A Lubet; Reid Townsend; Margie L Clapper; M Margaret Juliana; Vernon E Steele; David L McCormick; Clinton J Grubbs
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-05

6.  Zinc supplementation suppresses 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis.

Authors:  Louise Y Y Fong; Yubao Jiang; Maysoon L Rawahneh; Karl J Smalley; Carlo M Croce; John L Farber; Kay Huebner
Journal:  Carcinogenesis       Date:  2011-01-18       Impact factor: 4.944

7.  Targeted expression of ornithine decarboxylase antizyme prevents upper aerodigestive tract carcinogenesis in p53-deficient mice.

Authors:  David J Feith; Anthony E Pegg; Louise Y Y Fong
Journal:  Carcinogenesis       Date:  2012-12-07       Impact factor: 4.944

8.  Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch carcinogenesis by a 5-lipoxygenase inhibitor, garcinol.

Authors:  Xin Chen; Xinyan Zhang; Ye Lu; Joong-Youn Shim; Shengmin Sang; Zheng Sun; Xiaoxin Chen
Journal:  Nutr Cancer       Date:  2012-11-08       Impact factor: 2.900

9.  Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.

Authors:  David L McCormick; Thomas L Horn; William D Johnson; Xinjian Peng; Ronald A Lubet; Vernon E Steele
Journal:  PLoS One       Date:  2015-10-30       Impact factor: 3.240

10.  Khaya senegalensis inhibits piroxicam mediated gastro-toxicity in wistar rats.

Authors:  Fatima Nnawodu Ishaq; Abdulkadir Umar Zezi; Temidayo Olutoyin Olurishe
Journal:  Avicenna J Phytomed       Date:  2014-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.